ARCA biopharma Inc (NASDAQ: ABIO)’s stock price has increased by 72.81 compared to its previous closing price of 1.71. However, the company has seen a 72.81% increase in its stock price over the last five trading sessions. Seeking Alpha reported 2022-05-03 that Activist is pushing ARCA biopharma to stop new developments and return cash to shareholders. Subsequently, management has started a strategic review.
Is It Worth Investing in ARCA biopharma Inc (NASDAQ: ABIO) Right Now?
Additionally, the 36-month beta value for ABIO is 1.21. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for ABIO is 14.31M and currently, short sellers hold a 1.28% ratio of that float. The average trading volume of ABIO on April 03, 2024 was 26.30K shares.
ABIO’s Market Performance
ABIO stock saw an increase of 72.81% in the past week, with a monthly gain of 75.89% and a quarterly increase of 76.10%. The volatility ratio for the week is 2.69%, and the volatility levels for the last 30 days are 3.50% for ARCA biopharma Inc (ABIO). The simple moving average for the last 20 days is 73.03% for ABIO stock, with a simple moving average of 58.16% for the last 200 days.
Analysts’ Opinion of ABIO
Many brokerage firms have already submitted their reports for ABIO stocks, with Ascendiant Capital Markets repeating the rating for ABIO by listing it as a “Buy.” The predicted price for ABIO in the upcoming period, according to Ascendiant Capital Markets is $2 based on the research report published on February 27, 2018 of the previous year 2018.
Dawson James, on the other hand, stated in their research note that they expect to see ABIO reach a price target of $3.75. The rating they have provided for ABIO stocks is “Buy” according to the report published on October 09th, 2013.
ABIO Trading at 77.50% from the 50-Day Moving Average
After a stumble in the market that brought ABIO to its low price for the period of the last 52 weeks, the company was able to rebound, for now settling with 36.81% of gains for the given period.
Volatility was left at 3.50%, however, over the last 30 days, the volatility rate increased by 2.69%, as shares surge +122.16% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +130.43% upper at present.
During the last 5 trading sessions, ABIO rose by +116.96%, which changed the moving average for the period of 200-days by +76.67% in comparison to the 20-day moving average, which settled at $1.8097. In addition, ARCA biopharma Inc saw 73.82% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for ABIO
The total capital return value is set at -0.2. Equity return is now at value -13.57, with -13.19 for asset returns.
Based on ARCA biopharma Inc (ABIO), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -17.91. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is 16.21.
Currently, EBITDA for the company is -7.3 million with net debt to EBITDA at 5.14. The liquidity ratio also appears to be rather interesting for investors as it stands at 59.01.
Conclusion
In conclusion, ARCA biopharma Inc (ABIO) has seen better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
